United Therapeutics Corporation (UTHR) said Monday its long-term Phase 3 ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension met its primary endpoint, reducing the risk of clinical worsening by 55% compared with placebo.
The drug candidate showed durable efficacy in delaying disease progression, with 80% of patients on dual background therapy and 70% classified as World Health Organization/New York Heart Association Functional Class II at baseline.
The company said it plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026.
Shares of United Therapeutics closed at $503.90 on Friday, up 0.06%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.